SCHEMBL4466873

SCHEMBL4466873

COc1cc2c(Oc3ccc(N)cc3)ncnc2cc1OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.68
PDGFRB P09619 3/20 0.68
FLT4 P35916 3/20 0.68
FLT3 P36888 2/20 0.68
IRAK1 P51617 1/20 0.60
IRAK4 Q9NWZ3 1/20 0.60
PDGFRA P16234 2/20 0.59
KIT P10721 1/20 0.59
KDR P35968 9/20 0.58
RET P07949 1/20 0.57
KIF5B P33176 1/20 0.57
EGFR P00533 4/20 0.54
LCK P06239 2/20 0.54
KDM1A O60341 2/20 0.53
RIPK2 O43353 1/20 0.52
EPHB2 P29323 1/20 0.52
BRAF P15056 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30406755 1.00 CSF1R (0.68) CSF1RPDGFRBFLT4FLT3IRAK1
SCHEMBL4023315 0.92 PDGFRB (0.75) CSF1RPDGFRBFLT4FLT3IRAK1
SCHEMBL4359665 0.91 CSF1R (0.81) CSF1RPDGFRBFLT4FLT3IRAK1
SCHEMBL1016085 0.89 PDGFRB (0.66) CSF1RPDGFRBFLT4FLT3IRAK1
SCHEMBL1011381 0.89 PDGFRB (0.66) CSF1RPDGFRBFLT4FLT3IRAK1
SCHEMBL2481753 0.88 LCK (0.66) CSF1RPDGFRBFLT4FLT3PDGFRA
SCHEMBL23158591 0.87 CSF1R (0.66) CSF1RPDGFRBFLT4FLT3IRAK1
SCHEMBL5202698 0.86 KDR (0.61) CSF1RPDGFRBFLT4FLT3IRAK1
SCHEMBL30002061 0.86 TRPA1 (0.61) CSF1RPDGFRBFLT4FLT3IRAK1
SCHEMBL18550520 0.86 TRPA1 (0.61) CSF1RPDGFRBFLT4FLT3IRAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11358949-B2 Carbamate and urea compounds as multikinase inhibitors ANGEX PHARMACEUTICAL, INC. (US) 2022-06-14 US disclosed
EP-3615526-B1 PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2021-08-04 EP disclosed
US-11053223-B2 Phenoxyquinazoline compounds and their use in treating cancer ASTRAZENECA AB (SE) 2021-07-06 US disclosed
US-20210163445-A1 CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS ANGEX PHARMACEUTICAL, INC. 2021-06-03 US disclosed
US-20200223828-A1 PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA UK LIMITED (GB) 2020-07-16 US disclosed
EP-3615526-A1 PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca (SE) 2020-03-04 EP disclosed
WO-2018197643-A1 PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2018-11-01 WO disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-08-28 US disclosed
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-08-28 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11053223-B2 Phenoxyquinazoline compounds and their use in treating cancer KIT, ABL1, RB1 CSF1R 1131/4885PDGFRB 240/4885FLT4 88/4885
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 CSF1R 88/4885PDGFRB 202/4885FLT4 140/4885
US-20200223828-A1 PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER KIT, ABL1, RB1 CSF1R 1131/4885PDGFRB 240/4885FLT4 88/4885
US-11358949-B2 Carbamate and urea compounds as multikinase inhibitors UCK2, ULK2, CDK9 CSF1R 3544/4885PDGFRB 3279/4885FLT4 2239/4885
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same FLT3, TYRO3, ABL1 CSF1R 18/4885PDGFRB 159/4885FLT4 26/4885
US-20210163445-A1 CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS UCK2, ULK2, CDK9 CSF1R 3544/4885PDGFRB 3279/4885FLT4 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.